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■ CORRESPONDENCE ■
To the Editor:
Is there any such thing as a free lunch? Yes,
Most of us, physicians
and specialists alike, deny that our professional integrity
can be “bought” by something as trivial as a cup of coffee
or a free lunch. We all neglect the problem of interactions
between doctors and the pharmaceutical industry.
Considerable evidence from the social sciences suggests
that gifts of negligible value can influence the behavior
of the recipient in ways that the recipient does not always
realize [1]. Frequent general practitioner contact with
drug industry representatives is strongly and independ-
ently associated with higher prescribing costs [2].
Retail spending on prescription drugs is increasing
dramatically worldwide. For example, in the United
States, there was an increase of 17.1% from the year 2000
to US$154.5 billion in 2001. Spending is projected to
exceed US$500 billion by 2013 (US federal government
statistics). Total spending on pharmaceutical promotion
grew from US$11.4 billion in 1996 to US$29.9 billion in
2005. Although spending on direct-to-consumer adver-
tising increased by 330% during that time, it accounted
for only 14% of total promotional expenditures in 2005.
Though the number of letters sent by the Food and Drug
Administration (FDA) to pharmaceutical manufacturers
regarding violations of drug-advertising regulations fell
from 142 in 1997 to only 21 in 2006 [3], the practice of
the pharmaceutical industry and companies of spending
large amounts of money on buying lunches for physicians
has been widespread. In August 2006, the New York Times
ran an editorial decrying this practice and praising those
few institutions that have wisely banned free lunches.
One problem remains: Who is paying for drug
approvals? Who is using whom? Since 1992, the US has
relied heavily on the pharmaceutical industry to pay the
salaries of FDA scientists who review new drug applica-
tions. User fees now account for more than 40% of the
budget of the FDA division that reviews new drug
applications. In 2004, the public was shocked to learn
that rofecoxib (Vioxx, Merck) could remain in widespread
use for 5 years, even though the drug had been shown to
nearly double the risk of myocardial infarction and
stroke. Dr Avorn commented that, in regulatory policy, as
in grand rounds, there is no such thing as a free lunch [4].
What is the nature of the interactions between doc-
tors and the pharmaceutical industry? A questionnaire
was sent to 397 members of the American College of
Obstetricians and Gynecologists in 2003. The response
rate was 55%. Most respondents thought it proper to
accept gifts from pharmaceutical representatives, includ-
ing drug samples (92%), an informational lunch (77%),
an anatomic model (75%) or a well-paid consultant-
ship (53%). A third (33%) of the respondents thought
that their own decision to prescribe a drug would
probably be influenced by accepting drug samples [5].
Was it really only a third of them? A national survey of
3,167 physicians in six other specialties was performed,
also in 2003. The response rate was 52%. Most respon-
dents had some type of relationship with the pharma-
ceutical industry (94%), such as receiving food in the
workplace (83%) or receiving drug samples (78%).
More than a third (35%) received reimbursements for
costs associated with professional meetings or contin-
uing medical education. More than a quarter (28%)
received payments for consulting, giving lectures or
enrolling patients in trials [6]. In 1990, the American
Medical Association (AMA) policy addressed the ethical
issues regarding the industry’s gifts to physicians. Reim-
bursements for admission and travel to continuing
medical education meetings and tickets to cultural
and sporting events are clearly prohibited under the
AMA code. The AMA called on pharmaceutical com-
panies and physicians to abide by their respective
codes of conduct and to neither offer nor accept inap-
propriate gifts for the benefit of patients and the public
[7]. The physicians in the survey, who reported receiving
reimbursements for costs of travel, time, meals, lodging
or other personal expenses for attending meetings, were
acting against the guidelines of the Pharmaceutical
Research and Manufacturers of America (PhRMA) Code
on Interactions with Healthcare Professionals, 2002
(new code, 2007). The Code states clearly that any
industry support for conferences or courses should be
provided indirectly through event organizers [8]. Now,
we can get a picture of the relationships between the
great profession and the forces of capitalism, or the
profession of medicine and the pharmaceutical industry
(or simply, doctors and drug companies). Sometimes,
we forget about the third party, i.e. the patients.
“天下沒有(免費)白吃的午餐”.
PHYSICIAN–INDUSTRY INTERACTIONS: THERE IS
NO SUCH THING AS A FREE LUNCH
What about the interactions between medical
schools/students and the pharmaceutical industry? 
A questionnaire was sent to 723 students at Harvard
Medical School in 2003, with an overall response rate
of 58%. Twenty-six percent of respondents thought that
it was inappropriate for medical students to accept
gifts, 18% thought that the medical school curriculum
should provide information about the subject, and 61%
felt that they were not sufficiently well-informed on the
subject [9]. A national survey of 1,143 third-year stu-
dents at eight US medical schools, also in 2003, sug-
gested that student experiences and attitudes as a
group put them at risk for unrecognized influences by
marketing efforts [10]. Medical education on this eth-
ical subject seems to be urgently needed. Do we offer
enough information to our medical students, doctors
and specialists in Taiwan?
In response to “the high cost of free lunch” [11],
Dr Rankin (a paid speaker for Warner Chilcott,
Rockaway, NJ, USA) admitted that in the last 29 years,
the number of pharmaceutical company-supplied
lunches in his office had increased. He commented that
“my employees are happy to eat the free meal”. He
explained, “I spend 10 minutes with the drug represen-
tative in the office at any given time and eat the lunch
they provide also. I do not believe that this has ever
affected my prescription habits. I have, on occasion,
changed my prescribing habits based on scientific
information provided during these lunches, but this
was based on the information, not on the lunch. My
employees, who make no decisions as to the type of
drugs written, save money by not buying their lunches
that day and look at this as a benefit of their job.” [12]
Dr Campbell made a very good suggestion: “The focus
on solving the cost of the free lunch should be on
teaching physicians how to make decisions based on
objective data. Medical universities should develop
meticulous guidelines that will allow for the provision
of food, etc., by pharmaceutical companies when they
seek contact with physicians to advertise their product.
Teaching faculty and residents in training should receive
education about ethics and decision making as it per-
tains to influence on prescribing practice.” [13] In
conclusion, Drs Wall and Brown replied that the argu-
ment is often made that free samples benefit patients,
but these samples are not “free”; the cost of sample
medications is built into the marketing budgets of
drug companies. Other abuses (e.g. speakers’ fees to
physicians, direct-to-consumer advertising, off-campus
social events, kickbacks to pharmacies, special deals
for hospital formularies, etc.) do not undermine the
conclusions of their article; rather, they underscore the
fact that the pharmaceutical companies have enormous,
wide-ranging, powerful and worrisome influences on
the practice of medicine [14]. D.A. Randall (a company-
sponsored speaker training for Ketek, Sanofi-Aventis,
Bridgewater, NJ, USA) with regard to sampling, said,
“One byproduct of the physician–representative inter-
action is sampling. Although these involve more expen-
sive drugs, it remains a real benefit for patients.” [14]
Of course, any samples are not supposed to be resold.
One hopes that physicians retain some academic skill
when reviewing literature in journals and in maintain-
ing healthy skepticism regarding studies provided by
the pharmaceutical representatives. Although he admit-
ted that he may be revealing his naivety, he felt that 
“if I can sort through nonstraightforward illnesses and
difficult personalities of patients, I can select which
medication to use” [15].
Acceptable industry gifts, as defined by the American
College of Physicians’ guidelines on physician–industry
gifts, include inexpensive gifts for office use (pens and
calendars), low-cost gifts of an educational or patient
care nature (such as textbooks), and modest refresh-
ments [16]. The guidelines also say, “Ideally, physicians
should not accept any promotional gifts or amenities,
whatever their value or utility, if they have the ability to
cloud professional judgment and compromise patient
care.” PhRMA’s new code (April 18, 2007) governing
industry–health care professional relationships also states
clearly: “Interaction should not include entertainment.”
Interaction should occur at a venue conducive to pro-
viding scientific or educational information. Specifically,
this means no “dine and dash”, no entertainment, and
no recreational events (e.g. sporting events or spa vis-
its). Concerning medical education, “Companies can
provide support to the conference sponsor but should
not fund individual participants.” That means that a
company should not pay an individual’s tuition but
could provide support to the event sponsor. Concerning
consultation, “Legitimate consulting or advisory arrange-
ments are appropriate but token consulting arrange-
ments should not be used to justify payments to health
care professionals.” Finally, “Educational and practice-
related items may be provided to health care profes-
sionals, but should be for the health care benefit of
patients and of less-than-substantial value ($100 or
less). Items for the personal benefit of the health care
professional should not be offered or distributed. In
short, nothing should be offered or provided that would
interfere with the independence of the health care pro-
fessional’s prescribing practices.” Do we in Taiwan have
the same definition of substantial value ($100, about
NT$3,000, or less)? The World Medical Association’s
statement concerning the relationship between physi-
cians and commercial enterprises, approved in 2004,
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indicated that physicians should not receive a gift from
a commercial entity unless it is permitted by law and/or
by the policy of their National Medical Association, and
unless it conforms to the following conditions: (1) the
gift is only of nominal value; (2) the gift is not in cash;
(3) the gift, even one of nominal value, is not con-
nected to any stipulation that the physician prescribes
a certain medication, uses certain instruments or mate-
rials or refers patients to a certain facility. How many
of us have noticed this? In 2006, the Medical Ethics
Committee of the Department of Health, Taiwan, devel-
oped a statement concerning physician–industry rela-
tionships in Chinese, according to the World Medical
Association’s policy of 2004. In 2008, the American
College of Obstetricians and Gynecologists’ Committee
on Ethics offered revised recommendations regarding
relationships with industry to replace those of 2004
[17]. In summary, the committee’s opinion was that
obstetricians’ and gynecologists’ relationships with
industry should be structured in a manner that will
enhance, rather than detract from, their obligations to
their patients.
Are we going to set rules and guidelines on doctors’
relations with drug companies and learn how to dance
with porcupines [18,19], or are we going to push for
national legislature to enact laws and define what we do
as professionals? Grande [20] commented that if physi-
cians want prescriber profiling to end, they must act by
urging state legislatures to enact laws similar to those in
New Hampshire. Physicians should refuse to partici-
pate in marketing research that generates prescribing
patterns [20].
Dr Robert Goodman (a general internist at Columbia
University, New York City) established the No Free Lunch
Association (www.nofreelunch.org) in 1999. He encour-
ages doctors not to accept gifts from the drug indus-
try. The group wants doctors “to practice medicine on
the basis of scientific evidence rather than on the basis
of pharmaceutical promotion”. Members and support-
ers are physicians, pharmacists, dentists, nurse practi-
tioners, physician assistants, medical ethicists, and
others. Funding comes from membership fees, dona-
tions, and sales of products. There is no other outside
funding. On September 14, 2005, the American Academy
of Family Physicians (AAFP) said “yes” to McDonald’s
booth, “yes” to free lunches, and “no” to No Free Lunch
[21]. Seven days later, the AAFP changed its mind and
said “yes” to No Free Lunch to exhibit at its annual
meeting in the Moscone Center in San Francisco [22].
On March 27, 2006, the American College of Physicians
also said “yes” to No Free Lunch to having a booth at
its annual session in Philadelphia, and just about every-
thing else [23]. I do not know if we shall experience a
similar situation in the future, and see this happen in
Taiwan when we attend any annual meeting.
Horng-Jyh Tsai, MD, PhD, FACOG
Chief, Department of Obstetrics and Gynecology
Kuang Tien General Hospital
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